Sensei biotherapeutics presents promising clinical data from phase 1 dose escalation study of sns-101

- once every 3-week dosing of sns-101 demonstrates initial signs of promising clinical activity -  - pharmacokinetic and safety profile validate conditionally active approach -  - investor webcast to be held on monday, june 3 at 8:00 a.m. et - boston, may 23, 2024 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported encouraging clinical data from the dose escalation portion of its phase 1/2 trial of sns-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint vista (v-domain ig suppressor of t cell activation).
SNSE Ratings Summary
SNSE Quant Ranking